Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,122 stopped studies mapped to Lung Non-Small Cell Carcinoma and descendants · 90% state a reason
Over the 1,122 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02735850 | Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR)(ImmunoSABR) | Phase 2 | withdrawn | Apr 13, 2016 | Maastricht Radiation Oncology | Not yet submitted, unclear timelines | Other (stated, no rule matched) |
| NCT00801801 | Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With… | Phase 2 | terminated | Dec 4, 2008 | Francisco Robert,MD | Sponsors withdrew funding; preliminary efficacy data was not encouraging. | Efficacy / futility |
| NCT00455572 | Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With… | Phase 1 | terminated | Apr 3, 2007 | GlaxoSmithKline | Study early termination was due to slow recruitment and difficulties at achieving the required… | Enrollment / accrual |
| NCT02276560 | Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC(LCCC1407) | Phase 2 | terminated | Oct 28, 2014 | UNC Lineberger Comprehensive Cancer Center | This study was terminated due to lack of funding. | Funding |
| NCT02567396 | Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be… | Phase 1 | withdrawn | Oct 5, 2015 | National Cancer Institute (NCI) | Other- Protocol moved to Disapproved | Other (stated, no rule matched) |
| NCT02844140 | DE-CT in Lung Cancer Proton Therapy(DE-CT) | N/A | withdrawn | Jul 26, 2016 | Maastricht Radiation Oncology | not stated | Not stated |
| NCT02017925 | Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced… | N/A | withdrawn | Dec 23, 2013 | Ohio State University Comprehensive Cancer Center | not stated | Not stated |
| NCT00126451 | A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed… | Phase 2 | terminated | Aug 4, 2005 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT02087241 | Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung… | Phase 2 | terminated | Mar 14, 2014 | AstraZeneca | The sponsor decided to terminate the study. | Sponsor / business decision |
| NCT00526643 | CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients(CAPPA-2) | Phase 3 | terminated | Sep 10, 2007 | National Cancer Institute, Naples | scarce enrolment and presentation of positive results of similar study in June 2012. | Enrollment / accrual |
| NCT00351039 | Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in Elderly Patients With… | Phase 1 / Phase 2 | terminated | Jul 12, 2006 | H. Lee Moffitt Cancer Center and Research Institute | slow accrual | Enrollment / accrual |
| NCT01319669 | Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy | Phase 2 / Phase 3 | terminated | Mar 22, 2011 | Chinese Society of Lung Cancer | recruiting too slowly | Enrollment / accrual |
| NCT02095782 | Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor…(INNOVATE) | Phase 2 | terminated | Mar 26, 2014 | Guangdong Association of Clinical Trials | Because of the very slow enrollment, this study was stopped. | Enrollment / accrual |
| NCT00073008 | A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer | Phase 2 | terminated | Nov 17, 2003 | GlaxoSmithKline | Based on interim analysis at the end of Stage 1, and predefined stopping rules for futility,… | Efficacy / futility |
| NCT01731587 | Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung…(FINGERPRINT) | Phase 1 | withdrawn | Nov 22, 2012 | Merck KGaA, Darmstadt, Germany | The objectives of this trial are no longer deemed appropriate for the clinical development of… | Other (stated, no rule matched) |
| NCT01640847 | MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of… | Phase 2 | withdrawn | Jul 16, 2012 | Imunon | not stated | Not stated |
| NCT02319889 | Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma | Early Phase 1 | terminated | Dec 18, 2014 | Case Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT01026844 | Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer… | Phase 1 | terminated | Dec 4, 2009 | Massachusetts General Hospital | slow enrollment | Enrollment / accrual |
| NCT01383148 | Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer(TIME) | Phase 2 / Phase 3 | terminated | Jun 28, 2011 | Transgene | not stated | Not stated |
| NCT02795884 | Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC… | Phase 3 | withdrawn | Jun 10, 2016 | Yonsei University | Because of reconsideration of using erlotinib(EGFR Tyrosine kinase inhibitor) as adjuvant aim | Other (stated, no rule matched) |
| NCT02059889 | Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer | N/A | withdrawn | Feb 11, 2014 | Virginia Commonwealth University | slow accrual | Enrollment / accrual |
| NCT00921310 | Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | terminated | Jun 16, 2009 | Washington University School of Medicine | Withdrawal of funding from sponsor | Funding |
| NCT00352690 | A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage… | Phase 2 | terminated | Jul 17, 2006 | Washington University School of Medicine | Safety of patients | Safety / toxicity |
| NCT01377376 | A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib…(ATTENTION) | Phase 3 | terminated | Jun 21, 2011 | Kyowa Kirin Co., Ltd. | not stated | Not stated |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously… | Phase 1 / Phase 2 | withdrawn | Jan 22, 2016 | Case Comprehensive Cancer Center | Drug unavailable | Other (stated, no rule matched) |
| NCT00565227 | Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and… | Phase 1 | terminated | Nov 29, 2007 | University of Michigan Rogel Cancer Center | closed due to toxicity | Safety / toxicity |
| NCT01886573 | Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA… | Phase 1 | terminated | Jun 26, 2013 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01702714 | A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and… | Phase 1 | withdrawn | Oct 8, 2012 | Hoffmann-La Roche | Project Team decision | Other (stated, no rule matched) |
| NCT00642824 | A Genetic Substudy Associated With the Avastin (Bevacizumab) Study MO19390 in Patients… | Phase 2 | terminated | Mar 25, 2008 | Hoffmann-La Roche | Terminated due to low enrollment. No statistical analyses were performed. | Enrollment / accrual |
| NCT01015443 | Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in…(INSPIRE) | Phase 3 | terminated | Nov 18, 2009 | Merck KGaA, Darmstadt, Germany | The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide… | Sponsor / business decision |
| NCT02083679 | Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer | Phase 1 | terminated | Mar 11, 2014 | EMD Serono | Sponsor the return rights of the compound to the collaboration partner for further clinical… | Other (stated, no rule matched) |
| NCT01179269 | Pazopanib and Paclitaxel for Non-Small Cell Lung Cancer | Phase 2 | withdrawn | Aug 11, 2010 | Loyola University | The study was stopped because the research team was unable to enroll any participants | Enrollment / accrual |
| NCT01423760 | Common Safety Follow-up Trial of Tecemotide (L-BLP25) | N/A | terminated | Aug 26, 2011 | Merck KGaA, Darmstadt, Germany | The study is terminated prematurely as the sponsor decided to discontinue program with Tecemotide… | Sponsor / business decision |
| NCT01997775 | Metformin in Stage IV Lung Adenocarcinoma | Phase 2 | terminated | Nov 28, 2013 | National Cheng-Kung University Hospital | Difficult enrollment | Enrollment / accrual |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | Phase 1 | terminated | Apr 11, 2013 | Mirna Therapeutics, Inc. | Five immune related serious adverse events | Safety / toxicity |
| NCT00702572 | Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small… | Phase 1 | terminated | Jun 20, 2008 | Milton S. Hershey Medical Center | Low Enrollment | Enrollment / accrual |
| NCT01990261 | A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With…(STAR) | — | terminated | Nov 21, 2013 | Hoffmann-La Roche | not stated | Not stated |
| NCT00190476 | Elderly NSCLC/D vs DP (JCOG0207) | Phase 3 | terminated | Sep 19, 2005 | Japan Clinical Oncology Group | not stated | Not stated |
| NCT02895503 | Yoga in Improving Quality of Life in Patients With Non-small Cell Lung Cancer Undergoing… | N/A | terminated | Sep 9, 2016 | Virginia Commonwealth University | Lack of accrual/Slow accrual | Enrollment / accrual |
| NCT00807170 | Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain… | Phase 1 | terminated | Dec 11, 2008 | Sanofi | Very slow recruitment | Enrollment / accrual |
| NCT02126527 | Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent… | Phase 1 | withdrawn | Apr 30, 2014 | Mayo Clinic | no participants enrolled | Enrollment / accrual |
| NCT00404703 | A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in… | Phase 2 | terminated | Nov 29, 2006 | Hoffmann-La Roche | Primary (safety) endpoint reached | Safety / toxicity |
| NCT02522910 | An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel… | Phase 1 / Phase 2 | withdrawn | Aug 13, 2015 | Yonsei University | not stated | Not stated |
| NCT01915524 | Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small… | Phase 1 | terminated | Aug 5, 2013 | CureVac | Slow recruitment in stratum 3: enrolled only 2 instead of 8 pts. within predicted time | Enrollment / accrual |
| NCT01528137 | Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer… | Phase 1 | terminated | Feb 7, 2012 | Stanford University | Negative data from another trial led to termination of this trial by sponsor. | Other (stated, no rule matched) |
| NCT02673814 | Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously… | Phase 2 | withdrawn | Feb 4, 2016 | Peregrine Pharmaceuticals | not stated | Not stated |
| NCT00417248 | Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage… | Phase 1 / Phase 2 | terminated | Dec 29, 2006 | Nasser Hanna, M.D. | Negative sorafenib results from ESCAPE trial and safety concerns of regimen | Safety / toxicity |
| NCT01137162 | Clinical and Pathologic Studies of Patients Undergoing Treatment With EGFR Inhibitors | — | terminated | Jun 4, 2010 | Stanford University | Low Accrual | Enrollment / accrual |
| NCT02419170 | Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With… | Early Phase 1 | withdrawn | Apr 17, 2015 | Washington University School of Medicine | Investigator who manufactured the vaccine left the university. | Drug supply |
| NCT01798485 | A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in…(Galaxy 2) | Phase 3 | terminated | Feb 25, 2013 | Synta Pharmaceuticals Corp. | The study was stopped after the first Interim Analysis due to futility. | Efficacy / futility |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 23, 2017source: clinicaltrials